Trial · NCT07900659
Efficacy and Flexibility of Tildrakizumab Treatment in Patients With Moderate-to-severe Plaque Psoriasis and High Disease Burden
NCT07900659, Active not recruiting, Clin4all
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Flexibility of Tildrakizumab Treatment in Patients With Moderate-to-severe Plaque Psoriasis and High Disease Burden. Trials, record NCT07900659. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07900659
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Flexibility of Tildrakizumab Treatment in Patients With Moderate-to-severe Plaque Psoriasis and High Disease Burden
- NCT number
- NCT07900659
- Status
- Active not recruiting
- Enrollment
- 150 participants, actual
- Lead sponsor
- Clin4all
- Conditions
- Psoriasis, Moderate to Severe Psoriasis
- Interventions
- Psoriasis clinical assessment, Assessment of comorbidities, Quality of life evaluation, Well-being evaluation, Treatment compliance, Physical activity assessment
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Specific response to Tildrakizumab at Week28 (W28) | Week 28 | The response will be assessed by PASI absolute (Psoriasis Area and Severity Index), score from 0 to 72 |
| Secondary | Evaluate the maintenance of efficacy of Tildrakizumab | Week 52 and week 76 | Maintenance of treatment response will be assessed by PASI (Psoriasis Area and Severity Index) absolute at Week 52 and Week 76 according to Tildrakizumab dose (200mg or 100mg). |
| Secondary | Impact of treatment on perceived quality of life | Week 0, Week 28, Week 52 and Week 76 | Changes in the DLQI (Dermatology Life Quality Index) score. Description of each dimension of the DLQI (Dermatology Life Quality Index) score. The total score ranges from 0 to 30, and each of the 10 questions is scored on a 4 point Likert scale |
| Secondary | Impact of treatment on well-being | Week 0, Week 28, Week 52 and Week 76 | Changes in the well-being score assessed by the WHO-5 Well-Being Index, a short, self-reported questionnaire that measures current mental well-being over the past two weeks. Total sum of the 5 items, ranging from 0 (worst quality of life) to 25 (best quality of life). |
| Secondary | To study the safety of Tildrakizumab | Week 28, Week 52 and Week 76 | Describe the nature and frequency of adverse events throughout follow-up. |
| Other | To study and describe contributing elements to disease burden in real-life. | Week 0, Week 28, Week 52 and Week 76 | Assessment of comobidities. |
| Other | Profile's participants | Week 28, Week 52 and Week 76 | Identify participants profiles according to rapidity of response to treatment, its maintenance throughout follow-up and contributing elements to disease burden identified |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07900659
GET https://conductscience.org/api/trials/v1/NCT07900659/registered